By-health(SZ:300146) 光大证券研究·2025-03-25 08:53Core Viewpoint - The company reported a significant decline in revenue and net profit for the year 2024, indicating challenges in its operational performance and market conditions [2][3]. Revenue Performance - In 2024, the company achieved revenue of 6.838 billion yuan, a year-on-year decrease of 27.30%, and a net profit attributable to shareholders of 653 million yuan, down 62.62% [2]. - The main brand "汤臣倍健" generated revenue of 3.737 billion yuan, down 30.79%, while the joint care brand "健力多" reported revenue of 808 million yuan, down 31.51% [3]. - The company faced challenges due to a decline in foot traffic at offline pharmacies, product replacement issues, and inventory reduction efforts [3]. Channel Analysis - Revenue from offline channels decreased by 29.79%, with a total of 738 domestic and 49 overseas distributors, a reduction of 200 and 6 respectively compared to the end of 2023 [3]. - Online channel revenue fell by 25.35%, with offline channels experiencing greater pressure due to foot traffic and medical insurance impacts [3]. Cost and Profitability - The gross profit margin for 2024 was 66.69%, down 2.20 percentage points year-on-year, primarily due to intensified competition in online channels [4]. - The sales expense ratio increased to 44.33% for the year, reflecting a decline in sales expenses but a more significant drop in revenue [4]. - The net profit margin for 2024 was 9.47%, down 9.44 percentage points year-on-year, indicating a challenging profitability environment [4]. Strategic Initiatives - The company initiated a promotional campaign focusing on its two core product categories in Q4 2024 and plans to continue a big product strategy in 2025 [5]. - The company aims to launch an OTC version of "健力多" in H2 2025 to meet diverse consumer needs [3][5]. Future Outlook - The company anticipates continued low-price competition in online channels and plans to enhance its core competitiveness while stabilizing offline performance [6]. - Strategies include adjusting expense models, improving product distribution efficiency, and promoting new product iterations [6].